HA Pharmaceutical: Intends to reduce its stake in Renmin Tongtai by no more than 1%.

Haiyao Group announced that the company holds 434 million shares of Renmin Tongtai, accounting for 74.82% of the total. The company plans to reduce its holdings through centralized bidding by no more than 5.7988 million shares, accounting for less than 1% of the total shares of Renmin Tongtai. The reduction period is within three months after the disclosure of the announcement of Renmin Tongtai, and the reduction price will be determined based on the market price. On November 19, 2025, the company's board of directors approved the relevant proposal, which does not require the approval of the shareholders' meeting and does not constitute a related party transaction or a major asset restructuring.